Deferasirox

Essential medicine status

General description

INN	Deferasirox
ATC codes	V03AC03
Medicine type	Chemical agent
EML status history	First added in 2023 (TRS 1049) for Other specified sickle cell disorders or other haemoglobinopathies Added in 2023 (TRS 1049) for Thalassaemias
Therapeutic equivalent for	
Wikipedia	Deferasirox
DrugBank	Deferasirox

Recommendations

Section Medicines for haemoglobinopathies

- Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias